Aparna Mahakala, MD
Endocrinology, Diabetes & Metabolism · Lawrenceville, GANPI 1568550903
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 602 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 602 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Abbott$1K
- Lilly USA, LLC$1K
- Amgen$858
- Sanofi-aventis U.S. LLC$796
- AstraZeneca$719
- plus $5K from 39 others
What the payments were for
- Food & beverage$11,712100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,732 in reported general payments places this provider in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 366 | $666,117 |
| TrulicityDulaglutide | 113 | $230,789 |
| JardianceEmpagliflozin | 153 | $211,035 |
| MounjaroTirzepatide | 138 | $204,149 |
| Tresiba Flextouch U-100Insulin Degludec | 155 | $145,069 |
| FarxigaDapagliflozin Propanediol | 104 | $127,916 |
| JanuviaSitagliptin Phosphate | 68 | $81,821 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 59 | $75,661 |
| Tresiba Flextouch U-200Insulin Degludec | 43 | $72,382 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 54 | $68,598 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 50 | $60,436 |
| Novolog FlexpenInsulin Aspart | 120 | $54,392 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 34 | $42,539 |
| Humalog Kwikpen U-200Insulin Lispro | 14 | $41,873 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 45 | $33,151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,229 | $709,045434 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $1,106 | $446,580295 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $227 | $253,226194 claims |
| AstraZenecaFarxiga | $719 | $127,916104 claims |
| MerckJanuvia, Janumet | $46 | $112,69693 claims |
| AmgenProlia | $858 | $24,33114 claims |
| AbbVieSynthroid | $248 | $8,788107 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $122 | $7,659699 claims |
| Johnson & JohnsonInvokana | $80 | $7,23811 claims |
| Sanofi-aventis U.S. LLCLantus | $796 | $3,76121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Lawrenceville
- Adeniyi OdugbesanLawrenceville$636K
- David ShoreLawrenceville$83K
- David ArkinLawrenceville$15K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.